Catalio Capital Raises $400M to Back Biotech and Healthcare Startups
Catalio Capital secures $400M Fund IV to invest in biotech and healthcare startups, continuing its strong VC focus in the life sciences sector.
Matilda
Catalio Capital Raises $400M to Back Biotech and Healthcare Startups Catalio Capital Raises $400M Fund IV to Boost Biotech Innovation Catalio Capital has officially closed its $400 million Fund IV, reinforcing its commitment to supporting emerging healthcare and biotechnology companies. For those searching "Catalio Capital Fund IV details" or “Catalio’s new biotech fund 2025,” here’s what you need to know: this fund marks a major milestone in the firm's ongoing strategy to accelerate life sciences innovation. Since its founding in 2020, Catalio Capital Management has already invested in over 100 companies, and Fund IV is set to extend that momentum. With the average investment per startup set at $15 million, the firm is targeting high-impact ventures in diagnostics, drug discovery, and next-gen therapeutics. Image Credits:Nuthawut Somsuk / Getty Images Catalio Capital Fund IV fuels growth in healthcare startups Catalio Capital’s Fund IV is not just a financial vehicle—it’s a launchpad for cutting-edge healthcare solutions. Already, the fund h…